Before and After: MDC Website Redesign Comparison of the Minimum Deposit Casinos website before and after the comprehensive redesign. The updated site features streamlined navigation, enhanced functionality, a modern aesthetic, updated logo, and improved user-centric features. WATERFORD, Ireland, July 15, 2024 (GLOBE NEWSWIRE) — Minimum Deposit Casinos (MDC), a premier
Groundbreaking of new green hydrogen production facility in Budenheim, Germany Pictured left to right: Dr. Günter Krummel, Gesellschafter Trigona FCC; André Semann, CFO Budenheim; Meaghan McGuire, Head of Strategic Marketing, Hydrogen, BASF ECMS; Tim Ingle, SVP Precious Metal Services and Recycling, BASF ECMS; Saeed Alerasool, SVP R&D and Application, BASF
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment
LONDON, July 02, 2024 (GLOBE NEWSWIRE) — Leading international residence and citizenship advisory firm Henley & Partners, in partnership with Andan Foundation, a Swiss non-profit humanitarian organization, is pleased to announce the call for nominations for the 2024 Global Citizen Award. Created ten years ago in 2014, the Global Citizen
Adrian Ridge TEMECULA, Calif., July 01, 2024 (GLOBE NEWSWIRE) — Effective July 1, 2024, Adrian Ridge is Chief Executive Officer of Nikkiso Clean Energy & Industrial Gases Group, part of Nikkiso Co. Ltd.’s Industrial division. Ridge succeeds Peter Wagner, who remains engaged in a Board role as Executive Chairman for
Mr. Oliveira is an accomplished biopharmaceutical industry executive with nearly 25 years of commercial experience, building high-performing teams, and launching multiple successful pharmaceutical products WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based